PDEX - NASDAQ
Pro-Dex, Inc.
$66.88
-1.2%Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
At a Glance
Live SnapshotPro-Dex, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.
Pro-Dex, Inc. Cash Flow Statement
PDEX • NASDAQ
| Pro-Dex, Inc. Cash Flow Statement | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
9M | 2.1M | 7.1M | 4.6M | 4.6M | 6.1M | 4.1M | 1.6M | 5.1M | 822K | -365K | -488K | -1.8M | -876K | 2.6M | -3M | -2.8M | 317K | 506K | 827K | |
1.2M | 1.2M | 857K | 726K | 726K | 573K | 438K | 557K | 555K | 614K | 578K | 527K | 582K | 647K | 697K | 726K | 810K | 538K | 487K | 356K | |
140K | -1.6M | 264K | -63K | -63K | -22K | 1.4M | 391K | -2M | 0.0 | 0.0 | 0.0 | 0.0 | 885K | -2.7M | -91K | 1.1M | -434K | -177K | -84K | |
555K | 605K | 766K | 1.3M | 1.3M | 286K | 37K | 194K | 3K | 4K | 17K | 50K | 100K | 108K | 43K | 101K | 166K | 204M | 242M | 25M | |
-2.1M | 4.1M | -3.9M | -820K | -820K | 26K | -370K | 1M | -234K | -129K | -449K | -217K | 8K | -876K | 2.6M | 4.4M | 930K | -203M | -241.4M | -24.6M | |
(4.5M) | (1.9M) | (1.7M) | (1.6M) | (1.6M) | (683K) | (320K) | (401K) | (217K) | (21K) | (7K) | (7K) | (9K) | (56K) | (456K) | (154K) | (0.0) | (560K) | (0.0) | (0.0) | |
-10.5M | -225K | 396K | -6.5M | -6.5M | -1.1M | -2.3M | -694K | -125K | -845K | -556K | -201K | -177K | 157K | -464K | 1.1M | 1.6M | 627K | 107K | -1.5M | |
-1.7M | 6.2M | 5.5M | -847K | -847K | 5.9M | 3.3M | 3.1M | 3.2M | 466K | -775K | -329K | -1.3M | 45K | 2.9M | 3.2M | 1.7M | 2M | 1.5M | 55K | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-1.2M | -983K | -974K | -1.6M | -1.6M | -565K | -1.4M | -934K | -638K | -335K | -308K | -155K | -86K | -341K | -265K | -137K | -269K | -3.1M | -449K | -1.8M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -978K | (19K) | (30K) | (636K) | (24K) | -866K | (105K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -66K | -2.4M | |
(0.0) | -1.3M | (0.0) | -334K | -334K | -2.8M | -3M | -2.9M | -663K | -87K | -12K | -654K | -366K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
1.3M | 0.0 | 89K | 770K | 770K | 128K | 1.9M | 0.0 | 86K | 2M | 1.3M | 228K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-304K | 0.0 | 0.0 | -33K | -33K | 998K | 1.2M | -320K | -447K | -6K | -1.7M | 799K | -366K | 82K | 0.0 | 0.0 | 0.0 | 0.0 | -2M | 1K | |
-238K | -2.2M | -885K | -1.2M | -1.2M | -3.2M | -1.2M | -4.1M | -1M | (1.6M) | -1.5M | (323K) | -452K | -259K | -265K | -137K | -269K | -3.1M | -515K | -4.2M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-3.5M | -3.5M | -1.5M | -1.6M | -5.4M | -3.4M | -4M | 2M | -264K | -454K | -154K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -137K | 0.0 | 33K | 133K | |
3.5M | -816K | -809K | 756K | 8.8M | -630K | 4.5M | -78K | -59K | -30K | -15K | -5K | -775K | -357K | -1.8M | -433K | -660K | 1.4M | -877K | 1.8M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -23K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-3.5M | -3.5M | -1.5M | -1.6M | -5.5M | -3.4M | -4M | -220K | -312K | -454K | -154K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -137K | (0.0) | (0.0) | (0.0) | |
-305K | 50K | -134K | 60K | -4.1M | 39K | 51K | 38K | 73K | 500K | -34K | 1.5M | 66K | -6K | 26K | 0.0 | -45K | -196K | -76K | 0.0 | |
-292K | -4.3M | -2.5M | -790K | -790K | -4M | 450K | 2M | -298K | -457K | -203K | 1.5M | -709K | -363K | -1.7M | -433K | -842K | 1.2M | -920K | 1.9M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
-2.2M | -305K | 2.1M | -2.9M | -2.9M | -1.3M | 2.6M | 983K | 1.9M | 1.6M | -2.5M | 1.5M | -2.4M | -577K | 895K | 2.7M | 607K | 114K | 45K | -2.2M | |
2.6M | 2.9M | 849K | 3.7M | 3.7M | 7.7M | 5.2M | 4.2M | 2.3M | 697K | 3.2M | 1.7M | 4.1M | 4.7M | 3.8M | 1.1M | 517K | 403K | 358K | 2.6M | |
419K | 2.6M | 2.9M | 849K | 849K | 6.4M | 7.7M | 5.2M | 4.2M | 2.3M | 697K | 3.2M | 1.7M | 4.1M | 4.7M | 3.8M | 1.1M | 517K | 403K | 358K | |
-2.9M | 5.2M | 4.5M | -2.5M | -2.5M | 5.3M | 1.9M | 2.2M | 2.6M | 131K | -1.1M | -484K | -1.4M | -296K | 2.6M | 3.1M | 1.4M | -1.1M | 1M | -1.8M |
SEC Filings
PDEX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | January 29, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 19, 2025 | December 18, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 30, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your PDEX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.